The purpose of the present invention is to provide a novel antihuman CCR7 antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, a medicinal composition which comprises the antihuman CCR7 antibody, and so on. Provided is an antihuman CCR7 antibody binding specifically to the extracellular domain of human CCR7, said antihuman CCR7 antibody having a heavy chain CDR3 which comprises an amino acid sequence represented by SEQ ID NO: 7, 17, 27, 37, 47, 57, 67 or 77. Also provided is an antihuman CCR7 antibody which has heavy chain CDRs 1-3 and light chain CDRs 1-3, said heavy chain CDRs 1-3 and light chain CDRs 1-3 respectively comprising amino acid sequences represented by SEQ ID NOS:5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70 or 75-80. Preferably, such an antihuman CCR7 antibody has an activity of blocking CCR7-dependent intracellular signal transduction mechanism that is induced by stimulation with CCR7 ligands. The antihuman CCR7 antibodies according to the present invention are usable as the active ingredient of a therapeutic agent for tissue fibrosis or cancer.